Fibronostics is thrilled to announce its participation in the AASLD Liver Meeting 2025, the world’s leading conference dedicated to advancing liver science, research, and care.
The annual meeting of the American Association for the Study of Liver Diseases (AASLD) brings together global experts, clinicians, and innovators committed to improving liver health and tackling metabolic-associated liver diseases, such as MASH/MASLD.
Our leadership team, Brock Smith (CEO), Jonathan Berarducci (COO), and Mona Munteanu (CSO), will be attending the event & available at Booth #549.
We’re proud to share that Fibronostics will be presenting a new study on LIVERFASt, conducted in collaboration with Methodist Health System, Dallas, TX, during the poster communication session on November 10 under the track:
“MASLD/MASH – Therapeutics: New Agents and Approved/Available Agents.”
- 📄 Abstract ID: 4080
- 🔗 Read the abstract on the AASLD website
This study highlights the high efficacy of LIVERFASt in the non-invasive identification of MASH patients eligible for drug therapy and for monitoring treatment progress during ongoing management.
Compared to conventional diagnostic standards, LIVERFASt demonstrated exceptional performance in early detection and longitudinal follow-up, reaffirming its potential as a transformative tool for precision liver care.
We look forward to connecting with the hepatology community at AASLD 2025 and sharing how Fibronostics is turning data into better liver care.